• US Stocks
  • Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc.

NBIX
HealthcareLarge Cap 
  • $ 110.41

    Stock Price

  • -$ 0.83(-0.75%)

    Last Change

About the company

Neurocrine Biosciences Inc.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
View More
    Total Revenue
    $ 387.900 M
    Cost of Revenue
    $ 6.100 M
    Gross Profit
    $ 381.800 M
    Operating Income
    $ 87.800 M
Scripbox Recommended US Equity Funds
Want to get exposure to US Equity with the ease of Mutual Funds?Learn more

Price chart

$ 111.35

1D High

$ 110.08

1D Low

-$ 0.83 (-0.75%)

1D Change

Last updated on 

Previous Close
$ 111.24
Open Price
$ 0.00
52 Week High
$ 129.29
52 Week Low
$ 89.04
PE Ratio
62.38
Volume
104,762
Avg. Volume
613,722
Market Cap
$ 10.782 B
peers

Peers

Stock NameStock Price52 Week High52 Week LowCapital
Repligen Corp
Repligen Corp
$ 166.25$ 262.26$ 137.21Mid Cap
$ 143.12$ 162.75$ 128.24Large Cap
$ 1.59$ 33.25$ 0.50Small Cap
$ 57.40$ 65.89$ 32.16Small Cap
$ 32.34$ 53.25$ 31.77Large Cap
$ 778.18$ 800.78$ 331.80Large Cap
$ 30.45$ 35.77$ 25.17Large Cap
peers

Frequently Asked Questions

What is the price of Neurocrine Biosciences Inc. share today in India?

Today, on 28th Mar 2024, the price of Neurocrine Biosciences Inc. Shares in India is $ 110.41.

What was the highest Neurocrine Biosciences Inc. share stock price?

The highest Neurocrine Biosciences Inc. stock price was $ 129.29 till 28th Mar 2024 within the past 52 weeks.

What is the lowest price of NBIX shares?

The lowest NBIX stock price was $ 89.04 on 28th Mar 2024 within the past 52 weeks.

How to buy NBIX shares in India?

You can buy NBIX shares in India through Scripbox in just 4 simple steps. The process is simple, seamless, and paperless.
  • Create an account and submit KYC documents
  • On successful KYC, transfer amount required for investment
  • Invest in US stocks
  • Track and manage investments through Scripbox dashboard

Is Neurocrine Biosciences Inc. shares Listed on NSE or BSE?

No, NBIX shares are not listed on NSE or BSE. Neurocrine Biosciences Inc. is listed on the NASDAQ stock exchange.

Can I buy Neurocrine Biosciences Inc. shares in India?

Yes, you can buy Neurocrine Biosciences Inc. shares in India by simply opening an account with Scripbox.

Can I buy fractional shares of Neurocrine Biosciences Inc.?

Yes, you can buy fractional shares of Neurocrine Biosciences Inc. with Scripbox.

What is the P/E ratio for Neurocrine Biosciences Inc. shares?

As on 28th Mar 2024, the P/E ratio for Neurocrine Biosciences Inc. shares is 62.38.

What is the traded volume of Neurocrine Biosciences Inc. shares?

As on 28th Mar 2024, the traded volume for Neurocrine Biosciences Inc. shares is 104.762 undefined.

What is the market capitalization of Neurocrine Biosciences Inc. shares?

Neurocrine Biosciences Inc. shares has a market capitalization of $ 10.782 B.